ClinicalTrials.gg
RecruitingNCT06296186PREVAILUpdated Aug 27, 2026

Massed Prolonged Exposure for PTSD in Substance Use Treatment

An interventional study of Prolonged Exposure Therapy in Stress Disorders, Post-Traumatic and Substance Use Disorders, sponsored by Veterans Medical Research Foundation. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Veterans Medical Research Foundation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Stress Disorders, Post-Traumatic by Veterans Medical Research Foundation — 3 open to participants now, 3 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Veterans Medical Research Foundation.

Planned enrollment
3rd of 10
200 · median 152
Started
2024
with 1 other
No phase
10 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Stress Disorders, Post-Traumatic by Veterans Medical Research Foundation, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 with no phase, and was the 9th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

3 of the 11 studies in Stress Disorders, Post-Traumatic by Veterans Medical Research Foundation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Stress Disorders, Post-Traumatic by Veterans Medical Research Foundation, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if receiving Prolonged Exposure Therapy for PTSD in massed format (multiple sessions weekly) is as effective as receiving it with sessions once per week among veterans with PTSD and substance use disorder in intensive outpatient substance use treatment. The main questions it aims to answer are:

  • Will the massed format help participants complete and benefit from Prolonged Exposure in terms of PTSD symptoms?
  • Will it help participants reduce substance use? Participants who are in intensive substance use treatment will be asked to complete Prolonged Exposure with either weekly sessions or multiple sessions per week.
Read the detailed description

Posttraumatic stress disorder (PTSD) and substance use disorder (SUD) often co-occur. PTSD+SUD comorbidity is associated with more severe PTSD, worse treatment outcomes for substance use, greater suicide risk and worse functioning than having one of these disorders. First-line treatments for PTSD, particularly Prolonged Exposure Therapy (PE), are effective in treating PTSD among those with a SUD, and delivering these treatments concurrent to SUD programming is recommended by the VA/DoD Clinical Practice Guidelines. While PE is one of the most effective treatment options for PTSD among those with PTSD+SUD, effects are smaller and dropout is higher than among people with PTSD without a SUD. A promising way to enhance outcomes is to offer PE in a massed format (M-PE; i.e., multiple sessions per week instead of once weekly). M-PE has been shown to be effective in improving PTSD symptoms and substantially reducing dropout in military and Veteran populations. Preliminary findings suggest M-PE delivered concurrent to intensive SUD programming is a promising strategy that warrants further study. Evaluating the effectiveness of M- PE delivery in of SUD intensive outpatient programming (IOP) in improving PTSD and other mental health outcomes and reducing dropout as compared to weekly PE delivery (W-PE) is the necessary next step in this critical research.

The primary goal of this project is to determine if a promising way to treat PTSD among those with SUD, M-PE, will help Veterans with their PTSD symptoms and lead to better treatment completion rates more than PE delivered weekly and if the massed format will reduce substance use comparably to weekly PE among those in intensive SUD treatment. The study will also evaluate if M-PE helps Veterans function better and feel less depressed. M-PE is a one-on-one talk therapy that is delivered over twelve sessions several times a week. The therapy is brief because of the massed format so that it can be delivered at times when lengthy interventions may not be realistic, such as military mental health clinics on bases where military personnel may be getting ready to redeploy. The research team's preliminary work with Veterans in intensive SUD treatment showed M-PE to lead to improvements in PTSD and depression symptoms with no dropout, making this larger evaluation of M-PE compared to PE delivered in the traditional longer (weekly) format a critical next step. The study will accomplish this by randomly assigning participants who are in intensive SUD treatment to receive either M-PE or W-PE. The study will have 200 Veterans who served post 9/11 go through this study and the entire study is expected to take four years to complete. The study will run the study across four VAs (San Diego, Tampa, Chicago, and Atlanta).

03

Conditions studied

  • Stress Disorders, Post-Traumatic
  • Substance Use Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans
  • age 18+
  • who have served since September 2001
  • who are enrolled in a SUD IOP at a participating VA
  • meet criteria for a current SUD (Tobacco Use Disorder alone not sufficient for inclusion)
  • meet DSM-5 criteria for PTSD
  • report substance use at least 20 of the last 90 days
  • are able to give .

Exclusion criteria

Exclusion Criteria:

  • severe cognitive impairment
  • current suicidal or homicidal intent requiring immediate treatment
  • current unstable psychotic or manic symptoms not attributable to SUD
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Massed PE

    Prolonged Exposure delivered in a massed format - sessions multiple times per week

    Behavioral: Prolonged Exposure Therapy

  • Active comparator
    Weekly PE

    Prolonged Exposure delivered with weekly sessions

    Behavioral: Prolonged Exposure Therapy

Interventions

  • BehavioralProlonged Exposure Therapy

    Exposure therapy for PTSD

06

What researchers measure

Primary outcomes

  1. Clinician Administered PTSD Scale for DSM-5 (CAPS-5)

    Measures PTSD symptom severity, score range 0-80, higher scores mean greater symptom severity

    Time frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session

  2. Time Line Follow back (TLFB)

    Measures percent days of alcohol or other drug use, score range 0-100%, higher scores indicate greater percent days of use

    Time frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session

  3. Psychotherapy Completion Rates

    Percent of participants completing all sessions of psychotherapy, range is 0-100%, higher number means greater percent completed therapy

    Time frame: 16 weeks

Secondary outcomes

  1. Patient Health Questionnaire-9 (PHQ-9)

    Depression symptom severity, range = 0-27, higher scores mean greater depression symptom severity

    Time frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session

  2. Brief Psychosocial Functioning Inventory (B-IPF)

    Measures severity of impairment in psychosocial functioning, scores = 0-100, higher scores indicate greater impairment

    Time frame: At 4-, 16-, 28-, and 40-weeks post-first therapy session

  3. Client Satisfaction Questionnaire-8 (CSQ-8)

    Measures satisfaction with treatment, scores range from 8 to 32. higher scores indicate greater satisfaction with treatment

    Time frame: 16 weeks

07

Study locations

6 of 6 sites recruiting
  • VA San Diego Healthcare System
    San Diego, California 92161, United States
    Recruiting
  • VA Tampa Healthcare System
    Tampa, Florida 33612, United States
    Recruiting
  • VA Atlanta Healthcare System
    Atlanta, Georgia 30033, United States
    Recruiting
  • Hines VA Healthcare System
    Chicago, Illinois 60141, United States
    Recruiting
  • New Orleans VA Medical Center
    New Orleans, Louisiana 70119, United States
    Recruiting
  • Cleveland VA
    Cleveland, Ohio 44106, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Will share data with Strong Star Repository.

Supporting information: Study protocol

Time frame: After study completion.

Access criteria: Request to StrongStar Repository that Strong Star must approve.

Data sharing details ↗ · www.strongstar.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jul 2028, 46 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 46 months is above that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Mar 6, 2024
StartActual
Sep 1, 2024
Primary completionEst.
Jul 2028
CompletionEst.
Aug 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06296186
Lead sponsor
Veterans Medical Research Foundation
Collaborators
University of Minnesota, Center for Veterans Research and Education
Responsible party
Sponsor
First posted
Mar 6, 2024
Start date
Sep 1, 2024
Primary completion
Jul 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Sonya Norman, PhD
Contact
snorman@ucsd.edu
858-518-8266
Kaitlyn Panza, PhD
Contact
kaitlyn.panza@va.gov
858-552-8585
Shannon Kehle-Forbes, PhD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion